CSPC Pharmaceutical Group Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CSPC Pharmaceutical Group Limited
Chinese Newcomers Look For Niche Immuno-Oncology Opportunities
Chinese pharma companies are continuing to pile into the already overcrowded domestic anti-PD-1/L1 sector in China, but despite the competition and regulatory tightening, the latecomers are looking for opportunities in areas such as cervical and small cell lung cancer with relatively fewer contenders.
Deal Watch: Moderna, ElevateBio Subsidiary To Combine mRNA With Gene Editing
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.
Fewer Biotech-Pharma M&As But Tie-ups Indicate New China Trends
The past year witnessed only one major acquisition of a Chinese biotech by a major pharma company. However, some established firms such as Hansoh have set a new course for collaboration with much smaller peers by in-licensing preclinical assets.
Astellas Reports Second Phase III Win With Zolbetuximab In Stomach Cancer
The anti-Claudin-18.2 agent plus chemotherapy improves progression-free survival in inoperable or metastatic stomach cancer, following a similar Phase III readout in November.
- Medical Devices
- Research, Analytical Equipment & Supplies
- Generic Drugs
Drug Discovery Technologies
- Natural Products
- Molecular Diversity
- Large Molecule
- Other Names / Subsidiaries
- CSPC Megalith Biopharmaceutical Co., Ltd
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- NovaRock Biotherapeutics, Shijiazhuang Pharma Group
- China Shijiazhuang Pharmaceutical Group Co Ltd
- Hong Kong Tainuo Pharma Ltd
- Jiangsu Tainuo Pharmaceutical Co Ltd
- CSPC Pharmaceutical Group Co., Ltd.
- Shanghai Jinmante Biotechnology Co., Ltd.
- NBP Pharma
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.